Quality of life after complete lymphadenectomy for vulvar cancer: Do women prefer sentinel lymph node biopsy?

International Journal of Gynecological Cancer

Volumn 24, Issue 4, 2014, Pages 813-819

  Farrell, Rhonda ^a   Gebski, Val ^b   Hacker, Neville F ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Lymphoedema; Quality of life; Sentinel lymph node; Standard gamble; Vulvar cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; EARLY CANCER; FEMALE; FEMALE SEXUAL DYSFUNCTION; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LEG PAIN; LYMPH NODE DISSECTION; LYMPHEDEMA; MAJOR CLINICAL STUDY; PATIENT DECISION MAKING; PATIENT PREFERENCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; SOCIAL BEHAVIOR; STRUCTURED INTERVIEW; UTILITY BASED QUESTIONNAIRE CANCER; VERY ELDERLY; VULVA CANCER; CARCINOMA, SQUAMOUS CELL; COMPLICATION; DECISION MAKING; FOLLOW UP; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PSYCHOLOGY; UTILIZATION; VULVAR NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHOICE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHEDEMA; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; SENTINEL LYMPH NODE BIOPSY; VULVAR NEOPLASMS;

EID: 84900393485     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000101     Document Type: Article

References (25)

1. Ryan M, Stainton MC, Slaytor EK, et al. Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer. Aust N Z J Obstet Gynaecol. 2003;43:148-151.
2. Carlson JW, Kauderer J, Walker JL, et al. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: A Gynecologic Oncology Group Study. Gynecol Oncol. 2008;110:76-82.
3. Janda M, Obermair A, Cellas D, et al. Vulvar cancer patients? quality of life: a qualitative assessment. Int J Gynecol Cancer. 2004;14:875-881.
4. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008;26:884-889.
5. Oonk MH, van Os MA, de Bock GH, et al. A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol. 2009;113:301-305.
6. van der Velden J, van Lindert AC, Gimbrere CH, et al. Epidemiological data on vulvar cancer: comparison of hospital and population-based data. Gynecol Oncol. 1996;62:379-383.
7. Gonzales Bosquet J, Magrina JF, Gaffey TA, et al. Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol. 2005;97:828-833.
8. Hacker NF. Vulvar cancer. In: Berek JS, Hacker NF, eds. Berek and Hacker's Gynecologic Oncology. 5th ed. Lippincott Williams and Wilkins; Philadeliphia, US. 2010:554.
9. Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. J Clin Oncol. 2012;30:3786-3791.
10. Radziszewski J, Kowalewska M, Jedrzejczak T, et al. The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma. Gynecol Oncol. 2010;116:473-477.
11. De Hullu JA, Ansink AC, Tymstra T, et al. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. J Psychosom Obstet Gynaecol. 2001;22:199-203.
12. Grimison PS, Simes RJ, Stockler MR. Development and validation of optimally weighted measures of global health-related quality of life (QOL) and utility based on a cancer-specific QOL instrument. New South Wales, Australia: NHMRC Clinical Trials Centre, University of Sydney, Camperdown. 2007.
13. Rice W. A new probability model for determining exact P-values for 2 × 2 contingency tables when comparing binomial proportions. Biometrics. 1989;44:1-14.
14. Blinman P, King M, Norman R, et al. Preferences for cancer treatments: an overview of methods and applications in oncology. Ann Oncol. 2012;23:1104-1110.
15. Beesley V, Janda M, Eakin E, et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer. 2007;109:2607-2614.
16. Novackova M, Halaska MJ, Robova H, et al. A prospective study in detection of lower-limb lymphedema and evaluation of quality of life after vulvar cancer surgery. Int J Gynecol Cancer. 2012;22:1081-1088.
17. Bevilacqua JL, Kattan MW, Fey JV, et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25: 3670-3679.
18. Wong SL, Kattan MW, McMasters KM, et al. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12:282-288.
19. Vogel B, Leonhart R, Helmes AW. Communication matters: the impact of communication and participation in decision making on breast cancer patients' depression and quality of life. Patient Educ Couns. 2009;77:391-397.
20. Hack TF, Degner LF, Watson P, et al. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15:9-19.
21. Andersen MR, Sweet E, Lowe KA, et al. Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol. 2012;124:465-470.
22. Spencer SM, Carver CS, Price AA. Psychological and social factors in adaptation. In: Holland JC, Breitbart W, Jacobsen PB, et al, eds. Psycho-oncology. New York, NY: Oxford University Press; 1998:211-222.
23. Rouzier R, Haddad B, Plantier F, et al. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol. 2002;100: 1159-1167.
24. Tantipalakorn C, Robertson G, Marsden DE, et al. Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. Obstet Gynecol. 2009;113:895-901.
25. De Hullu JA, Hollema H, Lolkema S, et al. Vulvar carcinoma. The price of less radical surgery. Cancer. 2002;95: 2331-2338.